Skip to content
Open access

Upfront immune checkpoint inhibitors and long-term risk of major adverse cardiovascular events: a population-based propensity-matched cohort study

Oct 2026 · European Heart Journal · 0 citations

TL;DR

Findings support proactive cardiovascular risk assessment and optimization in long-term survivors while reinforcing that the excess risk is modest and should not deter use of these life-prolonging therapies.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but prior observational studies reported large relative increases in atherosclerotic cardiovascular events post-exposure. These estimates may be confounded by differences in treatment line and cumulative prior therapy. To evaluate the risk of major adverse cardiovascular events (MACE) in cancer patients treated with ICIs compared to matched patients treated with targeted regimens or epirubicin. Using linked administrative databases, we conducted a retrospective, population-based cohort study of adults initiating upfront systemic treatment for melanoma, lung, or breast cancer (2012–2024). The exposure group (ICIs) was matched 1:1 with controls receiving targeted regimens (Melanoma: BRAF/MEK; Lung: EGFR/ALK/ROS1/RET/MET) or epirubicin (Breast). Matching was based on sex, cancer site, and stage. The primary outcome (MACE) was a composite of acute myocardial infarction, stroke, or coronary revascularization (CABG/PCI), with death as a competing risk. Patients were followed from date of initiation of systemic treatment until the earliest of 5 years thereafter, death, loss of insurance eligibility (+7 days), or March 31, 2025. Crude mortality was assessed via Kaplan-Meier curves, and the Aalen-Johansen estimate was used for MACE incidence. Cause-specific hazards regression adjusting for age, hypertension, diabetes (DM), ischemic heart disease (IHD), heart failure (HF), atrial fibrillation (AF), stroke, peripheral arterial disease (PAD), and chronic obstructive pulmonary disease (COPD) was used to estimate the adjusted hazard ratio (HR) of the composite outcome in the ICI group relative to controls. Among 9,478 patients (4,739 matched pairs; 66.8% female; 76.1% lung, 17.2% breast, 6.7% melanoma), ICI recipients were slightly younger (median 67 vs. 69 years) with a higher baseline prevalence of IHD, PAD, and HF, but similar rates of HTN, DM, and stroke. Over mean follow-up of 463 days, there were 5,624 (59.3%) deaths and 3,514 (37.1%) MACE events. The median survival at 3 years was 31.4% (95% CI 29.8%-33.1%) in the ICI group and 40.2% (95% CI 38.7%-41.7%) for controls. The crude 3-year incidence of MACE was similar between groups (4.0%, 95% CI 3.4%-4.7% vs. 3.2%, 95% CI 2.7%-3.8%, p= 0.34). After multivariable adjustment, the cause-specific HR for MACE for the ICI group relative to controls was 1.34, 95% CI 1.07-1.67, p= 0.01). After adjustment, ICI therapy was associated with a 34% higher hazard of MACE compared to controls. Notably, this hazard ratio is lower than estimates from earlier observational studies that did not restrict to upfront treatment. These findings support proactive cardiovascular risk assessment and optimization in long-term survivors while reinforcing that the excess risk is modest and should not deter use of these life-prolonging therapies.HR for ICI-treated individuals vs. controls

Read PDF

Similar papers

Open access Sep 2026

Immune Checkpoint Inhibitor Therapy and Risk of Glomerular Disease: A Large Propensity-Matched Cohort Study

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but may cause immune-related kidney injury, and their association with glomerular disease remains incompletely understood. We evaluated the risk of incident glomerular disease following ICI therapy using the TriNetX U.S. Collaborative Network. Adult...

Ping-Huang Tsai, Wei-Cheng Chang, Hong-Jie Jhou et al. · 0 citations
Oct 2026

Survival Outcomes After Immune-Related Adverse Events in Older Adults With Advanced Non-Small Cell Lung Cancer.

BACKGROUND Immune-related adverse events (irAEs) are common toxicities of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC), but their prognostic implications in older adults remain uncertain. PATIENTS AND METHODS We conducted a retrospective cohort study using SEER-Medicare (2010-2019). We in...

O. Olateju, Meera Patel, R. Aparasu et al. · 0 citations
Open access Sep 2026

Immune-related adverse events and clinical outcomes in advanced non-small cell lung cancer: does more toxicity predict better outcomes?

Background Immune checkpoint inhibitors (ICIs) are a cornerstone of therapy for advanced non–small cell lung cancer (NSCLC). Elderly patients remain underrepresented in clinical trials, and the prognostic significance of immune-related adverse events (irAEs)—including their cumulative burden—across age groups is not fu...

A. Agbarya, N. S. Shrem, Asmah Miari et al. · 0 citations
Review Open access Oct 2026

Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial.

BACKGROUND Major adverse cardiovascular events (MACE) are a leading cause of noncancer death in men with prostate cancer (PCa). Androgen receptor pathway inhibitors (ARPIs) improve oncologic outcomes but may exacerbate cardiovascular risk. The Systematic Coronary Risk Evaluation 2(SCORE2) estimates 10-yr cardiovascular...

O. El-Taji, P. Dutey-Magni, Michael Brown et al. · 0 citations
Meta-analysis Open access Sep 2026

Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis

Higher pretreatment BMI was associated with longer adjusted OS and PFS in patients receiving ICI therapy, with the most consistent favorable association observed for obesity, warranting cautious interpretation.

Si-Yu Sun, Jun-Hao Zhang, Yan Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.